CONF-ADA — ADA Standards of Care 2026, Section 8: Obesity and Weight Management

[DRAFT — authored 2026-04-18. Guideline reference.]

Source

American Diabetes Association. Standards of Care in Diabetes — 2026. Section 8: Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes. Diabetes Care. 2026;49(Suppl. 1).

External URL: ADA Standards of Care 2026 Section 8

Key Updates vs. 2025 Edition

New Endorsements Integrating Late-2025 Trial Data

Oral semaglutide 14 mg — CV outcomes endorsement: SOUL trial (PMID: 40162642) supports use of oral semaglutide in T2D with established ASCVD or CKD for MACE reduction. First CV-outcomes endorsement for an oral GLP-1 agent.
Semaglutide for PAD functional benefit: STRIDE trial (PMID: 40169145) supports consideration of semaglutide 1 mg weekly in patients with T2D + symptomatic PAD (Fontaine stage IIa) for walking-capacity and quality-of-life improvements.
Wegovy HD (semaglutide 7.2 mg weekly): Approved by FDA March 19, 2026 via Commissioner's National Priority Voucher pathway. Guidance notes:
- Titration from 2.4 mg required; minimum 4 weeks at 2.4 mg before escalation.
- Dysesthesia (altered sensation) is a new at-dose-escalation warning; generally self-limited.
- Mean weight loss 20.7% at 72 weeks (STEP UP trial, Wharton & Kushner 2025 Lancet Diabetes Endocrinol).
EMA NAION classification: EMA PRAC (June 2025) classified NAION as a "very rare" semaglutide side effect (~1 per 10,000 person-years). US label status unchanged as of publication — practitioners advised to counsel on this emerging signal.

Preserved 2025 Recommendations

Tirzepatide and semaglutide remain preferred for chronic weight management.
Compounded products not endorsed.
Maintenance of weight loss requires indefinite therapy.

Retatrutide & Pipeline

Retatrutide (LY3437943) remains investigational; no clinical recommendation yet. Phase 3 TRIUMPH ongoing.
CagriSema (cagrilintide/semaglutide fixed-dose) pending regulatory review following REDEFINE-1 and -2 (2025-2026 data). Guideline notes: "May represent next-generation option pending approval; no clinical recommendation pre-approval."

Framework for Agent Selection (Updated)

Clinical Priority	First-line Agent	Supporting Evidence
Maximum weight reduction + good tolerance	Tirzepatide 15 mg	SURMOUNT-1 (PMID-35658024)
Maximum weight reduction on semaglutide base	Wegovy HD 7.2 mg	STEP UP
T2D + ASCVD	Semaglutide or Tirzepatide	SELECT, SURMOUNT-CVOT (interim)
T2D + CKD	Semaglutide	FLOW
T2D + PAD (claudication)	Semaglutide 1 mg	STRIDE
T2D + established ASCVD/CKD, oral preferred	Oral semaglutide 14 mg	SOUL
MASH/MASLD	Tirzepatide or semaglutide	Sanyal, Newsome
Sleep apnea + obesity	Tirzepatide	SURMOUNT-OSA
HFpEF + obesity	Semaglutide or Tirzepatide	STEP-HFpEF, SUMMIT

Pediatric & Adolescent Section (Cross-Reference to Section 14)

SURPASS-PEDS (PMID: 40975112) and STEP TEENS (PMID: 36322838) provide the evidence base.
Tirzepatide and semaglutide endorsed for adolescents 12-17 years with T2D or severe obesity under specialist care.

Linked Peptides

Related References

Orchestrator Notes

Primary guideline anchor for Lesson 5.1 updates post-CLD 2026.
2026 edition replaces 2025 as current-standard citation.
Keep 2025 citation available where historical comparison is relevant.

CONF-ADA-StandardsOfCare-2026 – ADA Obesity and Weight Management T2DM